SMC approves adjuvant use of Imatinib – 2012

Imatinib (Glivec) has been accepted for restricted use within Scotland for certain high risk GIST adult patients. The SMC accepted that adjuvant imatinib for three years compared to one year significantly improved survival. However, this treatment has yet to be approved by NICE for England & Wales. Click here for full details from SMC.

Posted in GIST News.